- While the hype around psychedelic stocks and alternative mental health treatments has seemingly cooled over the past few months, the industry is still ripe with opportunity.
- Long-term investors looking to ride the wave of novel mental health treatments should pay close attention to the pipelines of newcomers in the space.
- Companies like Bright Minds Biosciences are focused on targeting alternative 5-HT receptors that presumably offer greater health benefits with less risk.
- Products that avoid hitting the 5-HT2B receptor seem to have the most long-term market potential.
For further details see:
Bright Minds Biosciences: A Search For The GW Pharmaceuticals Of The Psilocybin Space